What is the current price for "When will the FDA approve Intellia Therapeutics' lonvo-z?"?

The leading outcome "Yes" is currently trading at 64.5% probability.

How many markets are available for "When will the FDA approve Intellia Therapeutics' lonvo-z?"?

There are 3 markets available for this event on Kalshi.

What is the trading volume for "When will the FDA approve Intellia Therapeutics' lonvo-z?"?

Trading volume data is not currently available.

BackKKALSHI

When will the FDA approve Intellia Therapeutics' lonvo-z?

Yes65%

Vol$0.00

Markets3

65%

TradeTrade on Kalshi

Event Group

EventKALSHI

Single EventKALSHIScience and Technology

When will the FDA approve Intellia Therapeutics' lonvo-z?

Name: When will the FDA approve Intellia Therapeutics' lonvo-z?
Start: 2026-07-10T06:03:41.420Z
End: 2026-08-09T06:03:41.420Z

Part of: When will the FDA approve Intellia Therapeutics' lonvo-z?

Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema If the FDA approves Lonvoguran Ziclumeran, lonvo-z, for Hereditary Angioedema for marketing before X 1, Y then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.

YesLeading Yes Probability

65%

VolTotal Volume

$0.00

Markets

Trade on Kalshi

When will the FDA approve Intellia Therapeutics' lonvo-z?

Yes

65%

Vol

$0.00

Markets

Trade

Market Price Graph

3 markets tracked

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

kalshi

No data available

All Markets(3)

Market	Price
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)	65%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)	49%
When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)	32%

Markets (3)

Sort

KALSHIHealth

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs.

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)

If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs.

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)

If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs.

When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Intellia Therapeutics' lonvo-z?

When will the FDA approve Intellia Therapeutics' lonvo-z?

Market Price Graph

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

Rules & Resolution Criteria

Markets (3)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before 2028)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before October 2027)

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? (Before July 2027)

Share This Event